Systematic Review/meta-analysis on the Role of CB1R Regulation in Sleep-wake Cycle in Rats

Overview

Journal J Evid Based Med

Date 2024 Sep 26

PMID 39325651

Authors

Jianjun Xue

Ziqing Xu

Jie Zhang

Huaijing Hou

Long Ge

Kehu Yang

Affiliations

Soon will be listed here.

Abstract

Objective: A systematic review/meta-analysis was conducted to investigate the effect of cannabinoid type-1 receptor (CB1R) regulation on the sleep-wake cycle of rats and to provide new ideas and evidence-based basis for clinical research on the treatment of sleep disorders.

Methods: We searched Cochrane Library, PubMed, Web of Science, Embase, Chinese Biomedicine Literature Database (CBM), China National Knowledge Infrastructure, WanFang, and VIP databases for relevant papers, about the effects of CB1R agonists/antagonists on sleep-wake cycle in rats, from inception to November 2023. Two reviewers performed study screening, data extraction, and risk of bias assessment using the SYRCLE's risk of bias tool. Meta-analysis was performed using RevMan 5.3 software. Heterogeneity test was performed on the included studies (Test standard α = 0.1). I value was used to evaluate the heterogeneity. Forest plot was drawn, and p ≤ 0.05 indicates statistically significant difference.

Results: A total of 16 trials involving 484 experimental rats were included. The methodological quality evaluation results showed that the overall quality of the included studies was low. The results of the meta-analysis showed that single administration of CB1R agonists could shorten the wakefulness (W) time in the first 6 h (h) (standardized mean difference (SMD) = -2.52, 95% confidence interval (CI) (-3.83, -1.22), p = 0.0002) and 24 h (SMD = -0.84, 95% CI (-1.31, -0.36), p = 0.0005) after administration, prolong nonrapid eye movement sleep (NREM) time (SMD = 1.75, 95% CI (0.54, 2.95), p = 0.005) and rapid eye movement sleep (REM) time (SMD = 1.76, 95% CI (0.26, 3.26), p = 0.02), and increase REM frequency after administration (SMD = 1.67, 95% CI (0.98, 2.35), p < 0.00001), these results were all statistically different. There were no significant differences in sleep latency and average duration of REM. Single administration of CB1R antagonists prolonged the first 6 h W time after administration (SMD = 1.36, 95%CI (0.29, 2.43), p = 0.01), shortened the first 6 h NREM time (SMD = -1.73, 95% CI (-2.88, -0.57), p = 0.003) and REM time (SMD = -2.07, 95% CI (-3.17, -0.96), p = 0.0003) after administration, and increased the frequency of W after administration (SMD = 3.57, 95% CI (1.42, 5.72), p = 0.001). There was no statistical difference in the average duration of W. REM time and REM frequency increased after continuous CB1R agonist withdrawal.

Conclusions: According to the existing evidence, CB1R played a pivotal role in regulating the sleep-wake cycle in rats. CB1R agonists tended to reduce W time, increase NREM and REM sleep times, boost REM frequency, and promote sleep. Conversely, CB1R antagonists could increase the duration and frequency of W, shorten NREM and REM sleep times, and promote W.

Citing Articles

Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.

Perez-Morales M, Espinoza-Abad R, Garcia-Garcia F Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006078 PMC: 11860062. DOI: 10.3390/ph18020266.

Systematic review/meta-analysis on the role of CB1R regulation in sleep-wake cycle in rats.

Xue J, Xu Z, Zhang J, Hou H, Ge L, Yang K J Evid Based Med. 2024; 17(4):714-728.

PMID: 39325651 PMC: 11684501. DOI: 10.1111/jebm.12643.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Perez-Morales M, Fajardo-Valdez A, Mendez-Diaz M, Ruiz-Contreras A, Prospero-Garcia O . 2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation. Neuroreport. 2014; 25(18):1437-41. DOI: 10.1097/WNR.0000000000000287. View

Galiegue S, MARY S, Marchand J, Dussossoy D, Carriere D, Carayon P . Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232(1):54-61. DOI: 10.1111/j.1432-1033.1995.tb20780.x. View

Suraev A, Marshall N, Vandrey R, McCartney D, Benson M, McGregor I . Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev. 2020; 53:101339. DOI: 10.1016/j.smrv.2020.101339. View

Macias-Triana L, Romero-Cordero K, Tatum-Kuri A, Vera-Barron A, Millan-Aldaco D, Arankowsky-Sandoval G . Exposure to the cannabinoid agonist WIN 55, 212-2 in adolescent rats causes sleep alterations that persist until adulthood. Eur J Pharmacol. 2020; 874:172911. DOI: 10.1016/j.ejphar.2020.172911. View

Xie J, Wang L, Ren W, Wang C, Gao J, Chen H . An α-hemoglobin-derived peptide (m)VD-hemopressin (α) promotes NREM sleep via the CB cannabinoid receptor. Front Pharmacol. 2023; 14:1213215. PMC: 10347404. DOI: 10.3389/fphar.2023.1213215. View

Mendez-Diaz M, Ruiz-Contreras A, Cortes-Morelos J, Prospero-Garcia O . Cannabinoids and Sleep/Wake Control. Adv Exp Med Biol. 2021; 1297:83-95. DOI: 10.1007/978-3-030-61663-2_6. View

Bogathy E, Papp N, Tothfalusi L, Vas S, Bagdy G . Additive effect of 5-HT2C and CB1 receptor blockade on the regulation of sleep-wake cycle. BMC Neurosci. 2019; 20(1):14. PMC: 6427841. DOI: 10.1186/s12868-019-0495-7. View

Pava M, Makriyannis A, Lovinger D . Endocannabinoid Signaling Regulates Sleep Stability. PLoS One. 2016; 11(3):e0152473. PMC: 4816426. DOI: 10.1371/journal.pone.0152473. View

10.

Goonawardena A, Plano A, Robinson L, Platt B, Hampson R, Riedel G . A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats. Sleep Disord. 2013; 2011:178469. PMC: 3581240. DOI: 10.1155/2011/178469. View

11.

Murillo-Rodriguez E, Cabeza R, Mendez-Diaz M, Navarro L, Prospero-Garcia O . Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport. 2001; 12(10):2131-6. DOI: 10.1097/00001756-200107200-00018. View

12.

Petrunich-Rutherford M, Calik M . Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals. Adv Exp Med Biol. 2021; 1297:97-109. DOI: 10.1007/978-3-030-61663-2_7. View

13.

Herrera-Solis A, Vasquez K, Prospero-Garcia O . Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. Pharmacol Biochem Behav. 2010; 95(1):106-12. DOI: 10.1016/j.pbb.2009.12.014. View

14.

Hu S, Mackie K . Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol. 2015; 231:59-93. DOI: 10.1007/978-3-319-20825-1_3. View

15.

Perez-Morales M, De la Herran-Arita A, Mendez-Diaz M, Ruiz-Contreras A, Drucker-Colin R, Prospero-Garcia O . 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. Pharmacol Biochem Behav. 2013; 108:1-7. DOI: 10.1016/j.pbb.2013.04.006. View

16.

Low Z, Lee X, Soga T, Goh B, Alex D, Kumari Y . Cannabinoids: Emerging sleep modulator. Biomed Pharmacother. 2023; 165:115102. DOI: 10.1016/j.biopha.2023.115102. View

17.

Haack M, Engert L, Besedovsky L, Goldstein M, Devine J, Dang R . Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways. Sleep. 2023; 46(6). PMC: 10262178. DOI: 10.1093/sleep/zsad061. View

18.

Bogathy E, Papp N, Vas S, Bagdy G, Tothfalusi L . AM-251, A Cannabinoid Antagonist, Modifies the Dynamics of Sleep-Wake Cycles in Rats. Front Pharmacol. 2019; 10:831. PMC: 6675864. DOI: 10.3389/fphar.2019.00831. View

19.

Calik M, Carley D . Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats. Sleep. 2017; 40(9). PMC: 5806547. DOI: 10.1093/sleep/zsx112. View

20.

Godos J, Grosso G, Castellano S, Galvano F, Caraci F, Ferri R . Association between diet and sleep quality: A systematic review. Sleep Med Rev. 2021; 57:101430. DOI: 10.1016/j.smrv.2021.101430. View